Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242604 | 1.00 | TK1 (0.53) | TK1DHFRALBALDH1A1LMNA | |
| Phosphoric Acid SCHEMBL3095605 | 0.93 | TK1 (0.52) | TK1DHFR | |
| SCHEMBL9549703 | 0.91 | TK1 (0.50) | TK1DHFRALBALDH1A1LMNA | |
| SCHEMBL9549708 | 0.90 | TK1 (0.48) | TK1DHFRALBALDH1A1LMNA | |
| Pyrophosphoric Acid SCHEMBL1269545 | 0.89 | POLB (0.54) | TK1DHFRPOLB | |
| SCHEMBL9549653 | 0.89 | TK1 (0.50) | TK1DHFRALBALDH1A1LMNA | |
| Triphosphate SCHEMBL81707 | 0.87 | POLB (0.55) | TK1DHFRPOLB | |
| SCHEMBL3154831 | 0.86 | POLB (0.57) | TK1DHFRPOLB | |
| SCHEMBL9549656 | 0.86 | TK1 (0.50) | TK1DHFRALBALDH1A1LMNA | |
| SCHEMBL5318941 | 0.85 | TK1 (0.48) | TK1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071254-A1 | POLYMERASE MEDIATED END MODIFICATION OF ABSEQ | BECTON DICKINSON CO (US) | 2026-03-12 | — | — | US | claimed |
| EP-4612322-A1 | POLYMERASE MEDIATED END MODIFICATION OF ABSEQ | Becton, Dickinson and Company (US) | 2025-09-10 | — | — | EP | claimed |
| CN-120019159-A | Polymerase mediated ABSEQ terminal modification | 贝克顿迪金森公司 | 2025-05-16 | — | — | CN | claimed |
| CN-119948173-A | Modified molecular beacons for improved detection specificity | 贝克顿迪金森公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| US-12173365-B2 | Sequencing using non-natural nucleotides | ULTIMA GENOMICS, INC. (US) | 2024-12-24 | — | — | US | claimed |
| CN-119095964-A | Multi-tail and multi-cap mRNA and uses thereof | 博德研究所 | 2024-12-06 | — | — | CN | claimed |
| EP-4466074-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | The Broad Institute Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| CN-118914407-A | Method for detecting dinucleotide in drinking water by solid phase extraction-nitrogen blowing concentration-liquid chromatography tandem mass spectrometry | 浙江大学 | 2024-11-08 | — | — | CN | claimed |
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | claimed |
| WO-1991005060-A2 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | APPLIED BIOSYSTEMS, INC. (US) | 1991-04-18 | — | — | WO | claimed |
| EP-0416011-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-03-13 | — | — | EP | claimed |
| EP-0378621-A1 | DIAGNOSTICS AND THERAPY FOR RHEUMATOID ARTHRITIS | GAY, Steffen (US) | 1990-07-25 | — | — | EP | claimed |
| EP-0362359-A1 | ANTIVIRAL COMPOSITION CONTAINING AROMATIC POLYCYCLIC DIONES AND NUCLEOSIDE ANALOGS AND METHOD FOR TREATING RETROVIRUS INFECTIONS | NEW YORK UNIVERSITY (US) | 1990-04-11 | — | — | EP | claimed |
| EP-0350287-A2 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | NeXstar Pharmaceuticals, Inc. (US) | 1990-01-10 | — | — | EP | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| WO-1989011285-A1 | DIAGNOSTICS AND THERAPY FOR RHEUMATOID ARTHRITIS | GAY STEFFEN (US) | 1989-11-30 | — | — | WO | claimed |
| WO-1989009056-A1 | ANTIVIRAL COMPOSITION CONTAINING AROMATIC POLYCYCLIC DIONES AND NUCLEOSIDE ANALOGS AND METHOD FOR TREATING RETROVIRUS INFECTIONS | NEW YORK UNIVERSITY (US) | 1989-10-05 | — | — | WO | claimed |
| WO-1989009055-A1 | ANTIVIRAL COMPOSITION CONTAINING AROMATIC POLYCYCLIC DIONES AND NUCLEOSIDE ANALOGS AND METHOD FOR TREATING RETROVIRUS INFECTIONS | NEW YORK UNIVERSITY (US) | 1989-10-05 | — | — | WO | claimed |
| EP-0272007-A2 | 5- and 6- Succinimidyl - carboxylate isomers of rhodamine dyes | APPLIED BIOSYSTEMS, INC. (US) | 1988-06-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071254-A1 | POLYMERASE MEDIATED END MODIFICATION OF ABSEQ | RNGTT, CTDSP1, DUT | TK1 212/4885DHFR 1251/4885ALB 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.